Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Neuraltus Pharmaceuticals

2483 E. Bayshore Road #212
Palo Alto, CA 94303
USA
650-424-1600
Website Company Summary Management Team
Management

CEO: Richard Casey (10/7/2013)
President/COO/Operations: John B Whelan (11/30/2014)
General Management: Gil Block (2009)
Finance: Bryan Millan
Board

Outside board: (May no longer be on the board) Annette Bianchi (VantagePoint Capital Partners Managing Director) James N Woody (Latterell Venture Partners Partner) Donald A McGovern (Pricewaterhouse Coopers Former Vice Chairman, Global Assurance)
Former outside board: Terry Gould (Adams Street Partners Partner)
Company

Business description: Neuraltus Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to developing and commercializing therapeutics that address critical unmet needs in the treatment of neurodegenerative diseases. Our lead product, NP001, is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease in the U.S. and motor neurone disease (MND) in Europe. Neuraltus has completed enrollment of a second Phase 2 clinical study of NP001 to confirm the previous Phase 2 findings in ALS patients with elevated levels of baseline inflammation. Neuraltus recognizes that ALS is a devastating condition with only two approved therapies, and we are focused on developing and bringing NP001 to market as quickly as possible. We strive to be a committed partner to the ALS community and work closely with patient advocacy organizations to better understand the needs of people affected by this disease.
Partners include: The Hospital for Sick Children ;  The Parkinson Institute
Capital

Rounds: 3
Recent Fundings: Dec 2011   Jan 2010
Capital raised: 29.6M
Last Round: 9.6M
Ownership: Private  

Last Tweets


 

Last Mentions


Overview
Record updated: Nov 2017
Sector: Biotech
Year Founded: 2005
Rounds: 3
Recent Fundings: Dec 2011   Jan 2010
Capital Raised: 29.6M
Last Round: 9.6M
Ownership: Private